The experience of key technical personnel who will be responsible for the day-to-day operation Maureen Sanderson, Ph.D., will replace Dr. Paul Juarez as MMC Co-leader in the next cycle, given her extensive involvement with the COC and affiliated research projects. She has training in epidemiology and biostatistics (Ph.D., Univ. of Washington, 1996) and is Professor of Obstetrics and Gynecology at MMC. Dr. Sanderson has 14 years experience as Pl for efiologic and intervenfion studies of prostate, breast and cervical cancer that focus on African Americans and Hispanics. She has extensive experience in collaborating with public health departments, community health centers, and other community partners on cancer research. Dr. Sanderson was recruited to MMC in 2008 to serve as the Senior Epidemiologist for the Partnership. She is also the Scienfific Director for the NCI-funded Meharry-CHC CNP (recenfiy renewed for a second cycle), and PI of the full research project (with Dr. Hull as Co-PI). Drs. Sanderson, Hull, and Khabele are currentiy conducfing a pilot study under the Partnership to test a culturally-tailored social markefing intervenfion for increasing HPV vaccine ufilizafion among Hispanic giris. Dr. Sanderson is co-investigator on an efiologic study of breast density funded by the DOD and on the NCI-funded P20, """"""""MMC-VICC: Partners in Cancer Sun/ivorship."""""""" Prior to joining MMC, she was Director of the Cancer and Training Cores of an NCMHD EXPORT planning grant at the University of Texas-Houston School of Public Health at Brownsville, which assessed the need for educational messages for women diagnosed with HPV. In 2005 Dr. Sanderson attended the same CBPR training institute as Dr. Hull mentioned above.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA163069-03
Application #
8534741
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
3
Fiscal Year
2013
Total Cost
$42,165
Indirect Cost
$29,390
Name
Meharry Medical College
Department
Type
DUNS #
041438185
City
Nashville
State
TN
Country
United States
Zip Code
37208
Umeukeje, Ebele M; Wild, Marcus G; Maripuri, Saugar et al. (2018) Black Americans' Perspectives of Barriers and Facilitators of Community Screening for Kidney Disease. Clin J Am Soc Nephrol 13:551-559
Vercruysse, Koen; Clark, Astiney; Alatas, Noor et al. (2018) Polysaccharide-mediated synthesis of melanins from serotonin and other 5-hydroxy indoles. Future Sci OA 4:FSO280
Hull, P C; Buchowski, M; Canedo, J R et al. (2018) Childhood obesity prevention cluster randomized trial for Hispanic families: outcomes of the healthy families study. Pediatr Obes 13:686-696
Sanderson, Maureen; Aldrich, Melinda C; Levine, Robert S et al. (2018) Neighbourhood deprivation and lung cancer risk: a nested case-control study in the USA. BMJ Open 8:e021059
Ochieng, Josiah; Nangami, Gladys; Sakwe, Amos et al. (2018) Impact of Fetuin-A (AHSG) on Tumor Progression and Type 2 Diabetes. Int J Mol Sci 19:
Tantawy, Mohammed N; Charles Manning, H; Peterson, Todd E et al. (2018) Translocator Protein PET Imaging in a Preclinical Prostate Cancer Model. Mol Imaging Biol 20:200-204
Burroughs, Andrea Flores; Eluhu, Sylvia; Whalen, Diva et al. (2018) PML-Nuclear Bodies Regulate the Stability of the Fusion Protein Dendra2-Nrf2 in the Nucleus. Cell Physiol Biochem 47:800-816
Ignacio, Rosa Mistica C; Lee, Eun-Sook; Wilson, Andrew J et al. (2018) Chemokine Network and Overall Survival in TP53 Wild-Type and Mutant Ovarian Cancer. Immune Netw 18:e29
Wilkins, Consuelo H (2018) Putting The Person In Personalized Medicine Personalized Medicine: Empowered Patients In The 21st Century? By Barbara Prainsack New York (NY) : NYU Press , 2017 288 pp., $30. Health Aff (Millwood) 37:823-824
Ignacio, Rosa Mistica C; Dong, Yuan-Lin; Kabir, Syeda M et al. (2018) CXCR2 is a negative regulator of p21 in p53-dependent and independent manner via Akt-mediated Mdm2 in ovarian cancer. Oncotarget 9:9751-9765

Showing the most recent 10 out of 178 publications